ESMO 2022 on the Randomized Phase 3 FORWARD I Study: Analyses of Patient-Reported Outcomes With Mirvetuximab Soravtansine vs. Standard Chemo in Ovarian Cancer

653 views
September 27, 2022
0 Comments
Login to view comments. Click here to Login